CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 147 enrolled
Drug / intervention
Influenza vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06738082
NCT06738082N/ACompleted

Influenza Vaccine Elicited Immune Response in Immunocompromised Patients

Insel Gruppe AG, University Hospital Bern·observational·Posted Dec 17, 2024·Updated Mar 26, 2025

In Brief

An observational study evaluating Influenza vaccine for Influenza Vaccine and Immunocompromised Patients. Completed, enrolled 147 participants across 1 site.

Detailed Summary

This study aims to understand how well influenza vaccines work in some individuals with weakened immune systems compared to healthy individuals. Some people, such as those with HIV, multiple sclerosis, certain cancers, or autoimmune conditions, have more severe influenza disease courses due to their medical treatments. These individuals may also respond less effectively to vaccines. By comparing immune responses to the influenza vaccine in both immunocompromised patients and healthy participants, this study aims to identify patterns in vaccine effectiveness and side effects. The goal is to find better ways to predict vaccine response in vulnerable patients and improve protection against influenza.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesSwitzerland
Collaborators--

Timeline

N/ACompletedFinished
20252026
First PostedDec 17, 2024
Enrollment StartOct 15, 2024
Primary CompletionJan 31, 2025
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 1.5 years ago

Interventions

Influenza vaccinebiological

Standard, commercially available, quadrivalent split-vaccine against influenza is given to all study participants.